Dupilumab
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Allergic Contact Dermatitis
Conditions
Allergic Contact Dermatitis
Trial Timeline
Dec 18, 2019 → Jul 31, 2026
NCT ID
NCT03935971About Dupilumab
Dupilumab is a approved stage product being developed by Regeneron Pharmaceuticals for Allergic Contact Dermatitis. The current trial status is active. This product is registered under clinical trial identifier NCT03935971. Target conditions include Allergic Contact Dermatitis.
What happened to similar drugs?
20 of 20 similar drugs in Allergic Contact Dermatitis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
20 competing products in Allergic Contact Dermatitis